Back to catalogue
OBD

Oxford Biodynamics PLC

Health Care First-pass screen £8.80m
230/1000 Overall fit
AI beneficiary 35% 18
Operating leverage 25% 25
Valuation 25% 27
Downside protection 15% 22

First-pass take

Pre-commercial genomics diagnostics company with zero AI exposure, deteriorating losses (£7.5m on £0.3m revenue), and material going-concern uncertainty. Flagship CiRT product remains unvalidated; customer concentration extreme (96% from concentrated base). Cash runway ~15 months post-fundraise; dilution inevitable.

Flags

loss-makinggoing-concernpre-commercialcustomer-concentrationcash-constraineddilution-riskbiotech-risk